Chronic sinusitis
Paratek Expands into Chronic Rhinosinusitis Market with $330M Optinose Acquisition
Paratek Pharmaceuticals, Optinose , XHANCE, Chronic rhinosinusitis, Nasal drug delivery, Pharmaceutical acquisition, Specialty pharma
AstraZeneca and Amgen’s Tezspire Shows Efficacy in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps, Despite Regulatory Risk Concerns
Tezspire, AstraZeneca, Amgen, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Phase 3 Trial, Regulatory Risk
Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps
Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.